Pfizer Inc

NYSE: PFE
$26.40
-$0.33 (-1.2%)
Real Time Data Delayed 15 Min.

PFE Articles

Apple, Intel, Pfizer, and Merck were the worst performing Dow stocks on Friday.
The top analyst upgrades, downgrades and initiations seen on Thursday included American Eagle Outfitters, Facebook, Nutrisystem, Pfizer, Roku, SeaWorld, Valero Energy and Zynga.
Pfizer reported mixed quarterly results before the markets opened on Tuesday and shares retreated in the premarket.
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
24/7 Wall St. has put together a preview of the Dow companies scheduled to report their quarterly results this week. Here, we have included the consensus earnings estimates from Thomson Reuters, as...
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider...
Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central...
Apple shares dipped again last week, but the company managed to hold onto its rank as the top-performing Dow stock for the year to date. Shares are up nearly 30% in 2018.
In 2017, 20 of the 30 stocks that comprise the Dow Jones Industrial Average posted double-digit, year-over-year share price gains. So far this year, only 9 currently show a double-digit gain.
For the second consecutive trading day, all 30 Dow stocks closed lower Thursday. Exxon, Chevron, Pfizer, and McDonald's were the biggest losers.
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan for its CEO.
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.